title: Feasibility of vaccination in preventing secondary cases of hepatitis A virus infection.
abstract: Although the secondary transmission of hepatitis A virus (HAV) infection is preventable through vaccination, it is not known whether the vaccination of household contacts is feasible. To this end, we conducted a prospective cohort study among the household contacts, 40 years of age or less, of all persons infected with primary HAV infection (index cases) and admitted to eight hospitals in southern Italy within 7 days of onset. Household contacts were vaccinated, and serum samples were taken at vaccination and after 14 and 45 days. Secondary cases were defined as those with IgM seroconversion occurring at least two weeks after enrollment. Coprimary cases were those assumed to have had the same exposure as the index case. Susceptible cases were those who were negative for both IgG and IgM. A total of 495 household contacts participated (acceptance rate of 65%); 65% were vaccinated within 4 days of admission of the index case and 95% within 7 days. At enrollment, 196 (39.6%) household contacts were immune (IgG-positive serum). During follow-up, 19 (3.8%) were IgM-positive: 13 (2.6%) were coprimary cases and 6 (1.2%; 95% CI: 0.2-3.2) secondary cases (5 identified at 14 days from vaccination and 1 at 45 days). Of the 241 susceptible cases, 192 (79.7%) had developed IgG antibodies at 14 days and only 3 (1.2%) did not develop IgG antibodies at 45 days. The 65% acceptance rate and the finding that 95% of the participating household contacts were vaccinated within 7 days of the index case's hospitalization indicate that timely vaccination is indeed feasible. The necessity of returning for the collection of blood samples probably decreased the acceptance rate.
authors.affiliation: A.O.G. Rummo, Benevento, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Sagliocca
authors.forename: E
authors.initials: E
authors.lastname: Bianco
authors.forename: P
authors.initials: P
authors.lastname: Amoroso
authors.forename: M
authors.initials: M
authors.lastname: Quarto
authors.forename: I
authors.initials: I
authors.lastname: Richichi
authors.forename: M E
authors.initials: ME
authors.lastname: Tosti
authors.forename: N
authors.initials: N
authors.lastname: Carannante
authors.forename: M
authors.initials: M
authors.lastname: Chironna
authors.forename: P
authors.initials: P
authors.lastname: Chiriacò
authors.forename: G
authors.initials: G
authors.lastname: Di Bari
authors.forename: P
authors.initials: P
authors.lastname: Lopalco
authors.forename: F
authors.initials: F
authors.lastname: Resta
authors.forename: T
authors.initials: T
authors.lastname: Santantonio
authors.forename: G
authors.initials: G
authors.lastname: Tantimonaco
authors.forename: A
authors.initials: A
authors.lastname: Mele
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D006506:Hepatitis A / Q000276:immunology / Q000517:prevention & control*; D017957:Hepatitis A Virus, Human / Q000276:immunology*; D006801:Humans; D008297:Male; D011446:Prospective Studies; D014761:Viral Hepatitis Vaccines / Q000276:immunology / Q000627:therapeutic use*
chemical_list: D014761:Viral Hepatitis Vaccines